Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Prostate cancer 2012: where do we stand and where are we heading?

McKay RR, Kantoff P.

Oncology (Williston Park). 2012 Dec;26(12):1222, 1224. No abstract available.

2.

Prostate cancer: what did we learn from the 2012 Annual Scientific Meeting of ASCO?

Burgess EF, Raghavan D.

Oncology (Williston Park). 2012 Dec;26(12):1216-21.

3.

New research reveals positive therapies and methods for treating prostate cancer.

Mitka M.

JAMA. 2012 Aug 1;308(5):441-2. doi: 10.1001/jama.2012.7960. No abstract available.

PMID:
22851092
4.

Choice of first-line treatment for metastatic prostate cancer.

[No authors listed]

Prescrire Int. 2013 Feb;22(135):51. No abstract available.

PMID:
23444511
5.

Successful use of Samarium 153 for emergency treatment of disseminated intravascular coagulation due to metastatic hormone refractory prostate cancer.

Ruffion A, Manel A, Valignat C, Lopez JG, Perrin-Fayolle O, Perrin P.

J Urol. 2000 Sep;164(3 Pt 1):782. No abstract available.

PMID:
10953152
6.

Prolonged survival with metastatic prostate cancer to bone.

Pisters LL, Troncoso P, Navone N.

J Urol. 1998 Jun;159(6):2100. No abstract available.

PMID:
9598540
7.

Stromal targeted therapy in bone metastatic prostate cancer: promise delivered.

Sartor O, Goeckeler W, Bruland O.

Asian J Androl. 2011 Nov;13(6):783-4. doi: 10.1038/aja.2011.120. No abstract available.

8.

[Prostate cancer: a review of therapeutic strategies].

Winterhalder RC.

Praxis (Bern 1994). 2009 Oct 7;98(20):1149-53. doi: 10.1024/1661-8157.98.20.1149. Review. German.

PMID:
19809978
9.

[Treatment of prostate cancer].

Romics I.

Orv Hetil. 2010 Apr 4;151(14):580-3. doi: 10.1556/OH.2010.28810. Hungarian. No abstract available.

PMID:
20332076
10.

Advanced prostate cancer. Endocrine therapies and palliative measures.

Taub M, Begas A, Love N.

Postgrad Med. 1996 Sep;100(3):139-40, 143-6, 152 passim. Review.

PMID:
8795651
11.

Optimal therapy sequencing in metastatic castration-resistant prostate cancer.

Abouharb S, Corn PG.

Curr Oncol Rep. 2013 Jun;15(3):217-23. doi: 10.1007/s11912-013-0311-y. Review.

PMID:
23568599
12.

Carcinoma of the prostate: treatment of bone metastasis.

Scalliet P.

Acta Urol Belg. 1996 May;64(2):87-90. Review. No abstract available.

PMID:
8701821
13.

Oslerian Genomics for Prostate Cancer Oncology.

Meng JX, Levine R, Simons JW.

Oncology (Williston Park). 2016 Feb;30(2):200, 202. No abstract available.

14.

Initial therapy of advanced prostate cancer.

Ismail M, Gomella LG.

Compr Ther. 1997 Oct;23(10):649-55. Review. No abstract available.

PMID:
9327180
15.

New Treatment Options for Patients With Metastatic Prostate Cancer: What Is The Optimal Sequence?

van Dodewaard-de Jong JM, Verheul HM, Bloemendal HJ, de Klerk JM, Carducci MA, van den Eertwegh AJ.

Clin Genitourin Cancer. 2015 Aug;13(4):271-9. doi: 10.1016/j.clgc.2015.01.008. Review.

PMID:
25704270
16.

The management of prostate cancer in patients with a rising prostate-specific antigen level.

Fichtner J.

BJU Int. 2000 Jul;86(2):181-90;quiz ii-iii. Review. No abstract available.

17.

New treatments for men with castration-resistant prostate cancer: can we move from small steps to giant leaps?

Armstrong AJ.

Eur Urol. 2014 Feb;65(2):300-2. doi: 10.1016/j.eururo.2013.08.059. No abstract available.

PMID:
24054873
18.

Predictive value of the clinically and scintigraphically important bone lesions in hormone-refractory prostate cancer (HRPC).

Zafeirakis A, Limouris GS.

Clin Transl Oncol. 2009 Nov;11(11):773-4. No abstract available.

PMID:
19917544
19.

Current status of treatment for patients with metastatic prostate cancer.

Higano CS.

Can J Urol. 2005 Jun;12 Suppl 2:38-41. Review.

PMID:
16018832
20.

First-line treatment of metastatic prostate cancer. Androgen suppression for symptomatic disease.

[No authors listed]

Prescrire Int. 2013 Feb;22(135):48-51. Review.

PMID:
23444510

Supplemental Content

Support Center